J W Hay
Affiliation: University of Southern California
- Pharmacoeconomics of lipid-lowering agents for primary and secondary prevention of coronary artery diseaseJ W Hay
Department of Pharmaceutical Economics and Policy, University of Southern California, Los Angeles, USA
Pharmacoeconomics 15:47-74. 1999..But any proven opportunity for saving the lives of 25% of those dying from cardiovascular disease each year deserves to be considered with the utmost seriousness and urgency...
- Cost effectiveness of adalimumab for the treatment of ankylosing spondylitis in the United KingdomM F Botteman
Pharmerit North America LLC, Bethesda, MD, USA
Rheumatology (Oxford) 46:1320-8. 2007..This study evaluated the cost effectiveness of adalimumab vs conventional therapy in patients with active ankylosing spondylitis (AS)...
- Using pharmacoeconomics to value pharmacotherapyJ W Hay
Department of Clinical Pharmacy, Pharmaceutical Economics, and Policy, University of Southern California, Los Angeles, California, USA
Clin Pharmacol Ther 84:197-200. 2008....
- Economic burden of haematological adverse effects in cancer patients: a systematic reviewS Y Liou
Pharmerit North America LLC, Bethesda, Maryland 20814, USA
Clin Drug Investig 27:381-96. 2007..The objective of this review was to summarise the published literature on the economic burden of neutropenia, thrombocytopenia and anaemia as AEs of cancer treatment...